Page 139 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology KRAS TP53 cholangiocarcinoma

for the assessment of the quality of nonrandomized studies 26. Chen F, Sheng J, Li X, et al. Unveiling the promise
in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605. of PD1/PD-L1: A new dawn in immunotherapy
for cholangiocarcinoma. Biomed Pharmacother.
doi: 10.1007/s10654-010-9491-z
2024;175:116659.
16. Hill MA, Alexander WB, Guo B, et al. Kras and Tp53
mutations cause cholangiocyte- and hepatocyte-derived doi: 10.1016/j.biopha.2024.116659
cholangiocarcinoma. Cancer Res. 2018;78(16):4445-4451. 27. Lei Z, Ma W, Si A, et al. Effect of different PD-1 inhibitor
combination therapies for unresectable intrahepatic
doi: 10.1158/0008-5472.can-17-1123
cholangiocarcinoma. Aliment Pharmacol Ther.
17. Huang L, Guo Z, Wang F, Fu L. KRAS mutation: From 2023;58(6):611-622.
undruggable to druggable in cancer. Signal Transduct Target
Ther. 2021;6(1):386. doi: 10.1111/apt.17623
28. Kim JY, Jung J, Kim KM, Lee J, Im YH. TP53 mutations predict
doi: 10.1038/s41392-021-00780-4
poor response to immunotherapy in patients with metastatic
18. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 solid tumors. Cancer Med. 2023;12(11):12438-12451.
tumor suppressor gene: Important milestones at the various
steps of tumorigenesis. Genes Cancer. 2011;2(4):466-474. doi: 10.1002/cam4.5953
29. Mugarza E, Van Maldegem F, Boumelha J, et al. Therapeutic
doi: 10.1177/1947601911408889
KRAS G12C inhibition drives effective interferon-mediated
19. Ghidini M, Personeni N, Bozzarelli S, et al. KRAS mutation antitumor immunity in immunogenic lung cancers. Sci Adv.
in lung metastases from colorectal cancer: Prognostic 2022;8(29):eabm8780.
implications. Cancer Med. 2016;5(2):256-264.
doi: 10.1126/sciadv.abm8780
doi: 10.1002/cam4.592
30. Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1
20. Robles AI, Harris CC. Clinical outcomes and correlates of mutations and PD-1 inhibitor resistance in KRAS-mutant
TP53 mutations and cancer. Cold Spring Harb Perspect Biol. lung adenocarcinoma. Cancer Discov. 2018;8(7):822-835.
2010;2(3):a001016.
doi: 10.1158/2159-8290.cd-18-0099
doi: 10.1101/cshperspect.a001016
31. Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive
21. Formica V, Sera F, Cremolini C, et al. KRAS and BRAF value of TP53 and KRAS mutation status for response to
mutations in stage II and III colon cancer: A systematic review PD-1 blockade immunotherapy in lung adenocarcinoma.
and meta-analysis. J Natl Cancer Inst. 2022;114(4):517-527. Clin Cancer Res. 2017;23(12):3012-3024.
doi: 10.1093/jnci/djab190 doi: 10.1158/1078-0432.ccr-16-2554
22. Maddah MM, Hedayatizadeh-Omran A, Moosazadeh M, 32. Gao G, Liao W, Ma Q, Zhang B, Chen Y, Wang Y. KRAS
Alizadeh-Navaei R. Evaluation of the prognostic role G12D mutation predicts lower TMB and drives immune
of TP53 gene mutations in prostate cancer outcome: suppression in lung adenocarcinoma. Lung Cancer.
A systematic review and meta-analysis. Clin Genitourin 2020;149:41-45.
Cancer. 2024;22(6):102226.
doi: 10.1016/j.lungcan.2020.09.004
doi: 10.1016/j.clgc.2024.102226
33. Budczies J, Romanovsky E, Kirchner M, et al. KRAS
23. Kealey J, Düssmann H, Llorente-Folch I, et al. Effect of TP53 and TP53 co-mutation predicts benefit of immune
deficiency and KRAS signaling on the bioenergetics of colon checkpoint blockade in lung adenocarcinoma. Br J Cancer.
cancer cells in response to different substrates: A single cell 2024;131(3):524-533.
study. Front Cell Dev Biol. 2022;10:893677.
doi: 10.1038/s41416-024-02746-z
doi: 10.3389/fcell.2022.893677
34. Frost N, Kollmeier J, Vollbrecht C, et al. KRAS G12C /TP53
24. Yousef A, Yousef M, Chowdhury S, et al. Impact of KRAS co-mutations identify long-term responders to first line
mutations and co-mutations on clinical outcomes in palliative treatment with pembrolizumab monotherapy
pancreatic ductal adenocarcinoma. NPJ Precis Oncol. in PD-L1 high (≥50%) lung adenocarcinoma. Transl Lung
2024;8(1):27. Cancer Res. 2021;10(2):737-752.
doi: 10.1038/s41698-024-00505-0 doi: 10.21037/tlcr-20-958
25. Peng J, Fang S, Li M, et al. Genetic alterations of KRAS and 35. Chen X, Wang D, Liu J, et al. Genomic alterations in
TP53 in intrahepatic cholangiocarcinoma associated with biliary tract cancer predict prognosis and immunotherapy
poor prognosis. Open Life Sci. 2023;18(1):20220652. outcomes. J Immunother Cancer. 2021;9(11):e003214.
doi: 10.1515/biol-2022-0652 doi: 10.1136/jitc-2021-003214

Volume 9 Issue 3 (2025) 131 doi: 10.36922/EJMO025120063